New Strong Buy Stocks for June 4th
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 04 2025
0mins
Should l Buy OPRX?
Source: NASDAQ.COM
Zacks Rank #1 Stocks: Five stocks have been added to the Zacks Rank #1 (Strong Buy) List, including BioCryst Pharmaceuticals, OptimizeRx, Bridgewater Bancshares, Palomar Holdings, and Ferrari, all showing significant increases in earnings estimates over the past 60 days.
Investment Opportunity: These stocks are considered strong investment opportunities with potential for substantial gains, as previous recommendations from Zacks have seen impressive returns ranging from +143.0% to +673.0%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OPRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OPRX
Wall Street analysts forecast OPRX stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 6.840
Low
17.00
Averages
24.33
High
32.00
Current: 6.840
Low
17.00
Averages
24.33
High
32.00
About OPRX
OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
OptimizeRx Shares Decline Amid Market Uncertainty
- Earnings Beat Expectations: OptimizeRx recently reported Q4 earnings of 51 cents per share, surpassing the consensus estimate of 23 cents, with revenues reaching $32.2 million compared to the expected $31.1 million, and adjusted EBITDA of $12.0 million, indicating a strong financial performance.
- 2026 Forecast Downgrade: The company updated its fiscal year 2026 guidance, projecting revenues between $109 million and $114 million, down from the previous forecast of $118 million to $124 million, while adjusted EBITDA is expected to fall between $21 million and $25 million, potentially creating near-term headwinds for the business.
- Increased Market Volatility: OptimizeRx shares fell 17.53% to $6.21 on Friday, trading 19.7% below its 20-day simple moving average and 50.1% below its 100-day SMA, indicating a bearish trend, with the stock positioned closer to its 52-week lows, suggesting a struggle for upward momentum.
- Analyst Rating Changes: Despite an average price target of $23.08 and a Buy rating, analysts from Stifel and Stephens & Co. have lowered their targets to $17.00, reflecting a cautious outlook on the company's future performance, which may impact investor confidence.
See More
OptimizeRx Exceeds Q4 2025 Expectations with Strong Financial Results
- Strong Financial Performance: OptimizeRx reported Q4 2025 revenue of $32.2 million and adjusted EBITDA of $12 million, exceeding market expectations and demonstrating successful adjustments in product mix and channel strategies.
- Gross Margin Improvement: The gross margin for Q4 2025 reached 74.8%, up from 68.1% in Q4 2024, reflecting optimization in solution and channel partner mix, which enhances profitability.
- Conservative 2026 Outlook: Management projects 2026 revenue between $109 million and $114 million, with adjusted EBITDA of $21 million to $25 million, indicating a cautious stance due to market uncertainties and client spending patterns.
- Share Repurchase Program: The Board authorized a $10 million share repurchase program to be financed through available cash and cash equivalents, aimed at enhancing shareholder value and addressing market volatility.
See More
OptimizeRx Reports Q4 2025 Earnings Beat with Strong EBITDA Growth
- Earnings Beat: OptimizeRx reported a Q4 2025 non-GAAP EPS of $0.51, surpassing expectations by $0.29, which highlights a significant improvement in profitability and boosts investor confidence.
- Slight Revenue Decline: The company generated $32.2 million in revenue for Q4 2025, a 0.3% year-over-year decrease, yet it exceeded market expectations by $1.29 million, indicating relative revenue stability in a competitive market.
- Significant EBITDA Growth: Adjusted EBITDA for Q4 2025 rose to $12.0 million, up 36.4% from $8.8 million in the same quarter of 2024, reflecting successful cost control and operational efficiency improvements.
- Annual Gross Profit Increase: For the full year 2025, gross profit reached $73.6 million, a 24.5% increase from $59.4 million in 2024, demonstrating ongoing improvements in profitability and market share.
See More
OptimizeRx Set to Announce Q4 Earnings on March 5
- Earnings Announcement: OptimizeRx is scheduled to release its Q4 earnings report on March 5, after market close, drawing significant attention from investors regarding its performance.
- Declining EPS Expectations: The consensus EPS estimate stands at $0.22, reflecting a 26.7% year-over-year decline, indicating potential profitability challenges for the company.
- Revenue Forecast Drop: The anticipated revenue for Q4 is $30.91 million, down 4.3% year-over-year, highlighting weakened market demand and increased competition.
- Historical Performance Metrics: Over the past two years, OptimizeRx has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, demonstrating a degree of effectiveness in managing performance expectations.
See More
Whetstone Capital Fully Exits GitLab Holdings
- Holding Change: Whetstone Capital Advisors reported in a February 13, 2026 SEC filing that it sold its entire 192,532-share stake in GitLab, with an estimated transaction value of approximately $8.68 million, indicating a significant loss of confidence in the company.
- Market Performance: As of February 12, 2026, GitLab shares were priced at $29.58, reflecting a 57.6% decline over the past year and trailing the S&P 500 by 70.5 percentage points, highlighting the challenges the company faces in a competitive landscape.
- Company Overview: GitLab is a leading provider of DevOps lifecycle software, focusing on streamlining and securing software development processes through a unified platform; however, it faces competitive pressure from AI-assisted coding and must adapt to market demands.
- Investor Focus: As companies reconsider vendor consolidation or adding AI layers, GitLab must standardize its platform and increase enterprise adoption to achieve sustained growth, particularly as demand weakens in some public sector segments and among smaller customers.
See More
Whetstone Capital Fully Exits GitLab Position
- Share Sale Details: Whetstone Capital Advisors sold all 192,532 shares of GitLab, with an estimated transaction value of $8.68 million, reflecting a significant decline in confidence towards GitLab, resulting in a quarter-end position value drop to zero.
- Asset Management Impact: This transaction represented 2.7% of Whetstone's 13F reportable AUM, down from 2.4% previously, indicating a notable shift in the fund's investment strategy regarding GitLab.
- Market Performance Analysis: As of February 12, 2026, GitLab shares were priced at $29.58, down 57.6% over the past year and lagging the S&P 500 by 70.5 percentage points, suggesting low market expectations for its future growth.
- Strategic Development Challenges: As a leading provider of DevOps lifecycle software, GitLab faces pressures from AI-assisted coding and the need for enterprises to simplify fragmented toolchains, necessitating a conversion of AI integration and customer engagement into sustained enterprise growth while maintaining operational leverage.
See More
OptimizeRx Shares Decline Amid Market Uncertainty
- Earnings Beat Expectations: OptimizeRx recently reported Q4 earnings of 51 cents per share, surpassing the consensus estimate of 23 cents, with revenues reaching $32.2 million compared to the expected $31.1 million, and adjusted EBITDA of $12.0 million, indicating a strong financial performance.
- 2026 Forecast Downgrade: The company updated its fiscal year 2026 guidance, projecting revenues between $109 million and $114 million, down from the previous forecast of $118 million to $124 million, while adjusted EBITDA is expected to fall between $21 million and $25 million, potentially creating near-term headwinds for the business.
- Increased Market Volatility: OptimizeRx shares fell 17.53% to $6.21 on Friday, trading 19.7% below its 20-day simple moving average and 50.1% below its 100-day SMA, indicating a bearish trend, with the stock positioned closer to its 52-week lows, suggesting a struggle for upward momentum.
- Analyst Rating Changes: Despite an average price target of $23.08 and a Buy rating, analysts from Stifel and Stephens & Co. have lowered their targets to $17.00, reflecting a cautious outlook on the company's future performance, which may impact investor confidence.
See More
OptimizeRx Exceeds Q4 2025 Expectations with Strong Financial Results
- Strong Financial Performance: OptimizeRx reported Q4 2025 revenue of $32.2 million and adjusted EBITDA of $12 million, exceeding market expectations and demonstrating successful adjustments in product mix and channel strategies.
- Gross Margin Improvement: The gross margin for Q4 2025 reached 74.8%, up from 68.1% in Q4 2024, reflecting optimization in solution and channel partner mix, which enhances profitability.
- Conservative 2026 Outlook: Management projects 2026 revenue between $109 million and $114 million, with adjusted EBITDA of $21 million to $25 million, indicating a cautious stance due to market uncertainties and client spending patterns.
- Share Repurchase Program: The Board authorized a $10 million share repurchase program to be financed through available cash and cash equivalents, aimed at enhancing shareholder value and addressing market volatility.
See More
OptimizeRx Reports Q4 2025 Earnings Beat with Strong EBITDA Growth
- Earnings Beat: OptimizeRx reported a Q4 2025 non-GAAP EPS of $0.51, surpassing expectations by $0.29, which highlights a significant improvement in profitability and boosts investor confidence.
- Slight Revenue Decline: The company generated $32.2 million in revenue for Q4 2025, a 0.3% year-over-year decrease, yet it exceeded market expectations by $1.29 million, indicating relative revenue stability in a competitive market.
- Significant EBITDA Growth: Adjusted EBITDA for Q4 2025 rose to $12.0 million, up 36.4% from $8.8 million in the same quarter of 2024, reflecting successful cost control and operational efficiency improvements.
- Annual Gross Profit Increase: For the full year 2025, gross profit reached $73.6 million, a 24.5% increase from $59.4 million in 2024, demonstrating ongoing improvements in profitability and market share.
See More
OptimizeRx Set to Announce Q4 Earnings on March 5
- Earnings Announcement: OptimizeRx is scheduled to release its Q4 earnings report on March 5, after market close, drawing significant attention from investors regarding its performance.
- Declining EPS Expectations: The consensus EPS estimate stands at $0.22, reflecting a 26.7% year-over-year decline, indicating potential profitability challenges for the company.
- Revenue Forecast Drop: The anticipated revenue for Q4 is $30.91 million, down 4.3% year-over-year, highlighting weakened market demand and increased competition.
- Historical Performance Metrics: Over the past two years, OptimizeRx has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, demonstrating a degree of effectiveness in managing performance expectations.
See More
Whetstone Capital Fully Exits GitLab Holdings
- Holding Change: Whetstone Capital Advisors reported in a February 13, 2026 SEC filing that it sold its entire 192,532-share stake in GitLab, with an estimated transaction value of approximately $8.68 million, indicating a significant loss of confidence in the company.
- Market Performance: As of February 12, 2026, GitLab shares were priced at $29.58, reflecting a 57.6% decline over the past year and trailing the S&P 500 by 70.5 percentage points, highlighting the challenges the company faces in a competitive landscape.
- Company Overview: GitLab is a leading provider of DevOps lifecycle software, focusing on streamlining and securing software development processes through a unified platform; however, it faces competitive pressure from AI-assisted coding and must adapt to market demands.
- Investor Focus: As companies reconsider vendor consolidation or adding AI layers, GitLab must standardize its platform and increase enterprise adoption to achieve sustained growth, particularly as demand weakens in some public sector segments and among smaller customers.
See More
Whetstone Capital Fully Exits GitLab Position
- Share Sale Details: Whetstone Capital Advisors sold all 192,532 shares of GitLab, with an estimated transaction value of $8.68 million, reflecting a significant decline in confidence towards GitLab, resulting in a quarter-end position value drop to zero.
- Asset Management Impact: This transaction represented 2.7% of Whetstone's 13F reportable AUM, down from 2.4% previously, indicating a notable shift in the fund's investment strategy regarding GitLab.
- Market Performance Analysis: As of February 12, 2026, GitLab shares were priced at $29.58, down 57.6% over the past year and lagging the S&P 500 by 70.5 percentage points, suggesting low market expectations for its future growth.
- Strategic Development Challenges: As a leading provider of DevOps lifecycle software, GitLab faces pressures from AI-assisted coding and the need for enterprises to simplify fragmented toolchains, necessitating a conversion of AI integration and customer engagement into sustained enterprise growth while maintaining operational leverage.
See More
